Bank of New York Mellon Corp raised its position in shares of AngioDynamics Inc. (NASDAQ:ANGO) by 2.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 427,529 shares of the company’s stock after buying an additional 9,502 shares during the period. Bank of New York Mellon Corp owned approximately 1.18% of AngioDynamics worth $6,145,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. BNP Paribas Arbitrage SA increased its position in shares of AngioDynamics by 99.2% in the second quarter. BNP Paribas Arbitrage SA now owns 8,174 shares of the company’s stock worth $117,000 after buying an additional 4,071 shares during the period. Arizona State Retirement System increased its position in shares of AngioDynamics by 3.8% in the first quarter. Arizona State Retirement System now owns 13,496 shares of the company’s stock worth $166,000 after buying an additional 500 shares during the period. Bank of Montreal Can acquired a new position in shares of AngioDynamics during the second quarter worth about $201,000. Jacobs Levy Equity Management Inc. acquired a new position in shares of AngioDynamics during the first quarter worth about $289,000. Finally, Acrospire Investment Management LLC acquired a new position in shares of AngioDynamics during the first quarter worth about $305,000. 70.01% of the stock is owned by hedge funds and other institutional investors.

AngioDynamics Inc. (NASDAQ:ANGO) traded up 0.52% during midday trading on Thursday, hitting $17.50. The stock had a trading volume of 155,912 shares. The company has a 50-day moving average price of $16.32 and a 200-day moving average price of $13.84. AngioDynamics Inc. has a 12-month low of $9.71 and a 12-month high of $17.54. The company’s market cap is $637.39 million.

AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Wednesday, July 13th. The company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.16 by $0.03. The business had revenue of $93.40 million for the quarter, compared to the consensus estimate of $88.64 million. AngioDynamics had a positive return on equity of 3.94% and a negative net margin of 12.57%. The company’s revenue was up 2.8% on a year-over-year basis. During the same period last year, the business posted $0.14 EPS. Equities analysts anticipate that AngioDynamics Inc. will post $0.63 EPS for the current year.

ANGO has been the subject of a number of research analyst reports. Zacks Investment Research raised AngioDynamics from a “hold” rating to a “buy” rating and set a $18.00 price target for the company in a report on Wednesday, September 14th. KeyCorp set a $18.00 price target on AngioDynamics and gave the company a “buy” rating in a report on Monday, September 12th. Four investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. AngioDynamics presently has an average rating of “Hold” and an average price target of $15.08.

In other AngioDynamics news, Director David F. Burgstahler sold 2,250,000 shares of AngioDynamics stock in a transaction that occurred on Friday, August 5th. The stock was sold at an average price of $14.62, for a total transaction of $32,895,000.00. Following the sale, the director now directly owns 23,988 shares in the company, valued at approximately $350,704.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Avista Capital Partners Gp, Ll sold 2,241,000 shares of AngioDynamics stock in a transaction that occurred on Friday, August 5th. The stock was sold at an average price of $14.62, for a total value of $32,763,420.00. The disclosure for this sale can be found here. Corporate insiders own 1.88% of the company’s stock.

AngioDynamics Company Profile

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

5 Day Chart for NASDAQ:ANGO

Want to see what other hedge funds are holding ANGO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AngioDynamics Inc. (NASDAQ:ANGO).

Receive News & Ratings for AngioDynamics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.